Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
Notice for atezolizumab (Roche Products Pty Ltd)
Active ingredients
atezolizumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
In combination with chemotherapy, is indicated for the adjuvant treatment of patients with Stage III, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colon cancer
Therapeutic area
Oncology